Skip to content

Nuvalent, Inc. NUVL Short-Term Investments

Short-Term Investments at other companies

Pfizer logo
PfizerPFE
$11.37B-28.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$175.69M+18,771%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$492.22M+229%
Exelixis logo
ExelixisEXEL
$551.06M-35.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$1.47B-17.1%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s short-term investments?
Nuvalent, Inc. (NUVL) reported short-term investments of $1.13B in Q1 2026.
How has Nuvalent, Inc.'s short-term investments changed year-over-year?
Nuvalent, Inc.'s short-term investments increased by 18.4% year-over-year, from $952.39M to $1.13B.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.